Combined EZH2 Inhibition and IKAROS Degradation Leads to Enhanced Antitumor Activity in Diffuse Large B-cell Lymphoma.
Tong KI, Yoon S, Isaev K, Bakhtiari M, Lackraj T, He MY, Joynt J, Silva A, Xu MC, Privé GG, He HH, Tiedemann RE, Chavez EA, Chong LC, Boyle M, Scott DW, Steidl C, Kridel R.
Tong KI, et al. Among authors: xu mc.
Clin Cancer Res. 2021 Oct 1;27(19):5401-5414. doi: 10.1158/1078-0432.CCR-20-4027.
Clin Cancer Res. 2021.
PMID: 34168051